{
    "clinical_study": {
        "@rank": "148073", 
        "arm_group": [
            {
                "arm_group_label": "LY2969822 (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of LY2969822 administered orally in 2 of 3 study periods."
            }, 
            {
                "arm_group_label": "Placebo (Part A)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo administered orally in 1 of 3 study periods."
            }, 
            {
                "arm_group_label": "LY2969822 (Part B)", 
                "arm_group_type": "Experimental", 
                "description": "LY2969822 administered orally for 14 days."
            }, 
            {
                "arm_group_label": "Placebo (Part B)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered orally for 14 days."
            }, 
            {
                "arm_group_label": "LY2969822 (Part C)", 
                "arm_group_type": "Experimental", 
                "description": "LY2969822 administered orally for 14 days."
            }, 
            {
                "arm_group_label": "Placebo (Part C)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered orally for 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it\n      causes any side effects. The study will also measure how much of the study drug gets into\n      the blood stream and how long it takes the body to get rid of the study drug. This is the\n      first time that this study drug is being given to participants. This study is for research\n      purposes only and is not intended to treat any medical condition."
        }, 
        "brief_title": "A Study of LY2969822 in Healthy Participants", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "Participants in Part A will complete three study periods, which together will last about 40\n      days. Participants in Parts B and C will complete one study period which will last about 17\n      days, but the total study time is about 40 days. Each participant may only enroll in one\n      part. Screening is required within 28 days prior to the start of the study for all\n      participants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male participants must agree to use a reliable method of birth control in addition to\n             having their partner use another method for the duration of the study and for 3\n             months after the last dose of LY2969822\n\n          -  Female participants must not be of child-bearing potential\n\n          -  Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter square\n             (kg/m^2), inclusive, at screening\n\n        Exclusion Criteria:\n\n          -  Have participated, within the last 30 days (prior to first dose in this study), in a\n             clinical trial involving an investigational product\n\n          -  Have a significant history of or current cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of\n             significantly altering the absorption, metabolism, or elimination of drugs; of\n             constituting a risk when taking the study medication; or of interfering with the\n             interpretation of data\n\n          -  Intended use of over-the-counter medication within 14 days prior to dosing or during\n             the study with the exception of vitamins and mineral supplements or occasional\n             paracetamol or acetaminophen\n\n          -  Intended use of herbal supplements or prescription medications, other than stable\n             doses of thyroid or estrogen hormone replacement, within 14 days prior to dosing or\n             during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018887", 
            "org_study_id": "15259", 
            "secondary_id": "I4W-FW-HMJD"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2969822 (Part A)", 
                    "LY2969822 (Part B)", 
                    "LY2969822 (Part C)"
                ], 
                "description": "Capsules administered orally", 
                "intervention_name": "LY2969822", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo (Part A)", 
                    "Placebo (Part B)", 
                    "Placebo (Part C)"
                ], 
                "description": "Capsules administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants With One or more Serious Adverse Events (SAEs) Considered by the Investigator to be Related to the Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through end of study (Week 6)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2969822", 
                "safety_issue": "No", 
                "time_frame": "Part A: Baseline up to 3 days. Parts B and C: Baseline up to 15 days"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2969822", 
                "safety_issue": "No", 
                "time_frame": "Part A: Baseline up to 3 days. Parts B and C: Baseline up to 15 days"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}